Effects of Preoperative Magnesium Sulphate Infusion on Emergence Agitation and Postoperative Quality of Recovery in Patients Undergoing Thoracoscopic Lobectomy.

IF 5.1 2区医学 Q1 CHEMISTRY, MEDICINAL

Drug Design, Development and Therapy Pub Date : 2025-05-29 eCollection Date: 2025-01-01 DOI:10.2147/DDDT.S503714

Yutian Pu, Xingyu Geng, Maosan Wang, Gaochao Lv, Ziwei Hu, Can Fang, Xinyue Zhang, Wanting Li, Xiaoxuan Fan, Xiuxia Chen

{"title":"Effects of Preoperative Magnesium Sulphate Infusion on Emergence Agitation and Postoperative Quality of Recovery in Patients Undergoing Thoracoscopic Lobectomy.","authors":"Yutian Pu, Xingyu Geng, Maosan Wang, Gaochao Lv, Ziwei Hu, Can Fang, Xinyue Zhang, Wanting Li, Xiaoxuan Fan, Xiuxia Chen","doi":"10.2147/DDDT.S503714","DOIUrl":null,"url":null,"abstract":"Background: Emergence agitation(EA) is common in the early phase of recovery from general anesthesia in adults, which can potentially cause unpredictable harm to both patients and medical staff. This study aimed to examine the effects of preoperative magnesium sulphate infusion on emergence agitation and postoperative quality of recovery in patients undergoing thoracoscopic lobectomy.Patients and methods: 84 patients undergoing thoracoscopic lobectomy were randomly assigned to either the magnesium sulphate group (group M) or the control group (group C). Group M received a 50 mg/ kg intravenous bolus of magnesium sulphate 20 minutes before induction, whereas group C was administered an equivalent volume of saline. The Riker Sedation-Agitation Scale (SAS) and the 40-item Quality of Recovery questionnaire (QoR-40) were used to evaluate emergence agitation and postoperative quality of recovery, respectively.Results: In comparison to group C, group M demonstrated a significantly lower incidence of EA (9.5% vs 42.9%; OR, 0.14; 95% CI, 0.04-0.47; P < 0.001) and dangerous agitation (0% vs 14.3%; OR, 2.17; 95% CI, 1.71-2.75; P =0.011), along with a reduction in the maximal SAS score (P < 0.05). Group M exhibited higher global QoR-40 scores than group C on postoperative day 1 (POD 1)(168.3±13.8 vs 155.6±16.5, P<0.001). Additionally, group M displayed lower Numerical rating scale (NRS) pain scores both at rest and during coughing in PACU and on POD 1 (P < 0.001). There were no significant statistically differences between the two groups in terms of time to extubation, incidence of delayed recovery and residual sedation (P > 0.05).Conclusion: Preoperative magnesium sulphate infusion effectively decreased the incidence and severity of EA in patients undergoing thoracoscopic lobectomy. Furthermore, it alleviated postoperative pain and improved postoperative quality of recovery, without an increase in adverse events.","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"4517-4525"},"PeriodicalIF":5.1000,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12129083/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Design, Development and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DDDT.S503714","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Emergence agitation(EA) is common in the early phase of recovery from general anesthesia in adults, which can potentially cause unpredictable harm to both patients and medical staff. This study aimed to examine the effects of preoperative magnesium sulphate infusion on emergence agitation and postoperative quality of recovery in patients undergoing thoracoscopic lobectomy.

Patients and methods: 84 patients undergoing thoracoscopic lobectomy were randomly assigned to either the magnesium sulphate group (group M) or the control group (group C). Group M received a 50 mg/ kg intravenous bolus of magnesium sulphate 20 minutes before induction, whereas group C was administered an equivalent volume of saline. The Riker Sedation-Agitation Scale (SAS) and the 40-item Quality of Recovery questionnaire (QoR-40) were used to evaluate emergence agitation and postoperative quality of recovery, respectively.

Results: In comparison to group C, group M demonstrated a significantly lower incidence of EA (9.5% vs 42.9%; OR, 0.14; 95% CI, 0.04-0.47; P < 0.001) and dangerous agitation (0% vs 14.3%; OR, 2.17; 95% CI, 1.71-2.75; P =0.011), along with a reduction in the maximal SAS score (P < 0.05). Group M exhibited higher global QoR-40 scores than group C on postoperative day 1 (POD 1)(168.3±13.8 vs 155.6±16.5, P<0.001). Additionally, group M displayed lower Numerical rating scale (NRS) pain scores both at rest and during coughing in PACU and on POD 1 (P < 0.001). There were no significant statistically differences between the two groups in terms of time to extubation, incidence of delayed recovery and residual sedation (P > 0.05).

Conclusion: Preoperative magnesium sulphate infusion effectively decreased the incidence and severity of EA in patients undergoing thoracoscopic lobectomy. Furthermore, it alleviated postoperative pain and improved postoperative quality of recovery, without an increase in adverse events.

查看原文本刊更多论文

术前硫酸镁输注对胸腔镜肺叶切除术患者急诊躁动及术后恢复质量的影响。

背景：出现性躁动（EA）在成人全麻恢复早期很常见，可能对患者和医务人员造成不可预测的伤害。本研究旨在探讨术前硫酸镁输注对胸腔镜肺叶切除术患者出现时躁动和术后恢复质量的影响。患者和方法：84例胸腔镜肺叶切除术患者随机分为硫酸镁组（M组）和对照组（C组）。诱导前20分钟，M组给予50 mg/ kg硫酸镁静脉滴注，C组给予等量生理盐水。采用Riker镇静-躁动量表（SAS）和40项恢复质量问卷（QoR-40）分别评估出现时躁动和术后恢复质量。结果：与C组相比，M组EA发生率显著降低(9.5% vs 42.9%；或者,0.14;95% ci, 0.04-0.47；P < 0.001)和危险的躁动(0% vs 14.3%；或者,2.17;95% ci, 1.71-2.75；P =0.011)，最大SAS评分降低（P < 0.05）。术后第1天（POD 1）， M组整体QoR-40评分高于C组（168.3±13.8 vs 155.6±16.5,PP < 0.001）。两组患者拔管时间、延迟恢复发生率及镇静残留情况比较，差异均无统计学意义（P < 0.05）。结论：术前输注硫酸镁可有效降低胸腔镜肺叶切除术患者EA的发生率和严重程度。此外，它减轻了术后疼痛，提高了术后恢复质量，没有增加不良事件。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Design, Development and Therapy CHEMISTRY, MEDICINAL-PHARMACOLOGY & PHARMACY

CiteScore

9.00

自引率

0.00%

发文量

382

审稿时长

>12 weeks

期刊介绍： Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design, discovery and development through to clinical applications. The journal is characterized by the rapid reporting of high-quality original research, reviews, expert opinions, commentary and clinical studies in all therapeutic areas. Specific topics covered by the journal include: Drug target identification and validation Phenotypic screening and target deconvolution Biochemical analyses of drug targets and their pathways New methods or relevant applications in molecular/drug design and computer-aided drug discovery* Design, synthesis, and biological evaluation of novel biologically active compounds (including diagnostics or chemical probes) Structural or molecular biological studies elucidating molecular recognition processes Fragment-based drug discovery Pharmaceutical/red biotechnology Isolation, structural characterization, (bio)synthesis, bioengineering and pharmacological evaluation of natural products** Distribution, pharmacokinetics and metabolic transformations of drugs or biologically active compounds in drug development Drug delivery and formulation (design and characterization of dosage forms, release mechanisms and in vivo testing) Preclinical development studies Translational animal models Mechanisms of action and signalling pathways Toxicology Gene therapy, cell therapy and immunotherapy Personalized medicine and pharmacogenomics Clinical drug evaluation Patient safety and sustained use of medicines.